Randomised Evaluation of COVID-19 Therapy

Brief summary

RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone) Community-acquired pneumonia: Corticosteroids (dexamethasone)

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

RECOVERY

status

RECRUITING

phase

PHASE3

study type

INTERVENTIONAL

enrollment

70000

sponsor

University of Oxford

conditions

Pneumonia

interventions

DRUG: Lopinavir-Ritonavir; DRUG: Corticosteroid; DRUG: Hydroxychloroquine; DRUG: Azithromycin; BIOLOGICAL: Convalescent plasma; DRUG: Tocilizumab; BIOLOGICAL: Immunoglobulin; DRUG: Synthetic neutralising antibodies; DRUG: Aspirin; DRUG: Colchicine

start date

2020-03-19

start date type

ACTUAL

primary completion date

2028-09-30

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters